All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1632 VU0463271 May 16 2024
E1340 Glesatinib May 16 2024
E1962 RMC-9805 May 15 2024
E1613 UNC8153 May 14 2024
E1818 PF-07265807 May 14 2024
E1830 Baxdrostat May 14 2024
E1745 Ulonivirine May 14 2024
E1724 CRT-0105446 CRT 0105446 (compound 22d) is a potent inhibitor of LIMK1 with an IC50 of 8 nM. It can inhibit the growth of MCF-7 breast cancer cells and the invasion of MDA-MB-231 cells by reducing the expression of phosphorylated cofilin. May 09 2024
E1875 BI-3231 BI-3231 is the potent and selective chemical probe, which inhibits hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) with an IC50 of 1 nM and Ki of 0.7 nM in the enzymatic assay. It has the potential to treat NASH and other liver diseases.  May 09 2024
E1937 PT-179 PT-179, an orthogonal Thalidomide derivative targets cereblon without causing off-target degradation effects. PT-179 specifically binds CRBN, forms a ternary complex with a target protein fused to a zinc finger (ZF) degron, and mediates the degradation of the tagged protein. May 09 2024
E1795 Triparanol(MER-29) Triparanol (MER-29) is an inhibitor of 24-dehydrocholesterol reductase (DHCR24), an enzyme involved in cholesterol biosynthesis. It exhibits antitumor properties, such as decreasing proliferation and inducing apoptosis in various cancer cell lines, while also reducing Hedgehog pathway signaling in these cells. May 09 2024
E0448 RO8191 RO8191 (CDM-3008, RO4948191), an imidazonaphthyridine compound, is an orally active and potent agonist of interferon (IFN) receptor. RO8191 binds directly to the IFNα/β receptor 2 (IFNAR2), activating IFN-stimulated genes (ISGs) expression and the phosphorylation of JAK/STAT signaling. May 09 2024
S7994 GSK864 GSK864 is a cell-penetrant, potent, and selective inhibitor of isocitrate dehydrogenase 1 (IDH1) mutants, specifically targeting the R132C, R132H, and R132G variants with IC50 values of 8.8 nM, 15.2 nM, and 16.6 nM, respectively. May 06 2024
E1929 LTGO-33 LTGO-33 is a potent and selective inhibitor of voltage-gated sodium channel NaV1.8. LTGO-33, with its potency in the nanomolar range, selectively inhibits NaV1.8 over 600 times more than human NaV1.1-NaV1.7 and NaV1.9. Its inhibition is not dependent on the state of the channels and displays consistent potency against both closed and inactivated conformations. LTGO-33 holds promise for research in pain disorders. Apr 28 2024
E1925 Butylhydroxyanisole Butylhydroxyanisole (Butylated hydroxyanisole; BHA; E320) is an inhibitor of ferroptosis, a food preservative and antioxidant that prevents the formation of harmful compounds, extending shelf life. However, it's associated with liver toxicity, reproductive organ development issues, learning delays, and sleep problems. Apr 25 2024
E1740 Mepazine hydrochloride Mepazine hydrochloride (Pecazine hydrochloride) is a potent and selective inhibitor of MALT1 protease, with IC50 values of 0.83 μM for GSTMALT1 full length and 0.42 μM for GSTMALT1 aa 325-760. It effectively suppresses the activation of the NF-kB pathway specifically in activated B cell subtype of diffuse large B cell lymphoma (ABC-DLBCL) cells and makes it a promising candidate for the treatment of ABC-DLBCL. Apr 25 2024
E1806 AGI-24512 AGI-24512 is an inhibitor of MAT2A with an IC50 of 8 nM. It increases R-Loop formation and DNA damage in MTAP-deleted and WT cell models. It also exhibits anti-proliferative activity in vitro. Apr 25 2024
E1798 HOIPIN-8 HOIPIN-8, is a potent inhibitor of linear ubiquitin chain assembly complex (LUBAC) and NF-κB signaling with an IC50 value of 11 nM. It serves as a powerful tool for investigating the physiological and cellular functions of LUBAC. Apr 23 2024
E1699 SR10221 SR10221 is a inverse-agonist of PPARγ with IC50 of 1.6 nM in RT112/84 FABP4-NLucP reporter assay. It exhibits an antiproliferative activity in vitro. Apr 22 2024
S8546 Alrizomadlin Alrizomadlin(APG-115, AA-115) is a highly potent and efficacious inhibitor of MDM2 and binds to MDM2 with IC50 of 3.8 nM. It exhibits potent antiproliferative and apoptogenic activities and also significantly reduces tumor burden and prolonged survival in AML xenograft models. Apr 21 2024